Description

SEBI issues a prohibitory order under Recovery Certificate No. 2885 of 2020 against Lars Walan in connection with the matter of Astrazeneca Pharma India Ltd., directing attachment of assets to recover dues.

Summary

SEBI has issued a prohibitory order against Lars Walan pursuant to Recovery Certificate No. 2885 of 2020 in the matter of Astrazeneca Pharma India Ltd. The order is an enforcement measure to recover outstanding dues owed to SEBI by directing the attachment or prohibition of disposal of assets held by the named individual.

Key Points

  • Prohibitory order issued against Lars Walan under Recovery Certificate No. 2885 of 2020
  • The matter pertains to Astrazeneca Pharma India Ltd.
  • The order directs the concerned parties (banks, depositories, etc.) not to allow disposal of assets of the named individual
  • Issued by the Recovery Officer under the SEBI Act for enforcement of dues
  • Part of SEBI’s ongoing enforcement and recovery proceedings

Regulatory Changes

No new regulatory changes introduced. This is an enforcement action under existing SEBI recovery and enforcement framework.

Compliance Requirements

  • Banks, depositories, and other financial institutions holding assets of Lars Walan are directed to comply with the prohibitory order
  • No disposal, transfer, or encumbrance of the attached assets is permitted
  • Entities receiving this order must acknowledge and act in accordance with its directives immediately

Important Dates

  • Recovery Certificate issued: 2020 (No. 2885 of 2020)
  • Prohibitory Order date: March 6, 2026

Impact Assessment

The impact is limited to the named individual (Lars Walan) and financial institutions holding his assets. There is no broader market or systemic impact. This is a routine SEBI enforcement/recovery action targeting non-compliance related to Astrazeneca Pharma India Ltd. proceedings. General investors and market participants are not affected.

Impact Justification

This is a targeted enforcement action against a specific individual (Lars Walan) under a 2020 recovery certificate related to Astrazeneca Pharma India Ltd. It has high severity as a legal enforcement order but low broader market impact since it applies to one named respondent and does not affect general market operations or trading rules.